Top

Published in:

01-06-2019 | Original Article

Resveratrol protects the brain against oxidative damage in a dopaminergic animal model of mania

Authors: Samira Menegas, Camila L. Ferreira, José Henrique Cararo, Fernanda F. Gava, Gustavo C. Dal-Pont, Maria L. Gomes, Jotele F. Agostini, Patrícia Fernanda Schuck, Giselli Scaini, Monica L. Andersen, João Quevedo, Samira S. Valvassori

Published in: Metabolic Brain Disease | Issue 3/2019

Abstract

The present study aimed to evaluate the effects of resveratrol on behavior and oxidative stress parameters in the brain of rats submitted to the animal model of mania induced by m-AMPH. In the first model (reversal treatment), rats received intraperitoneal (i.p.) injection of saline or m-AMPH (1 mg/kg body weight) once a day for 14 days, and from the 8th to the 14th day, they were orally treated with water or resveratrol (15 mg/kg), once a day. In the second model (maintenance treatment), rats were orally pretreated with water or resveratrol (15 mg/kg) once a day, and from the 8th to the 14th day, they received saline or m-AMPH i.p., once a day. Locomotor and exploratory activities were assessed in the open-field test. Oxidative and nitrosative damage parameters to lipid and proteins were evaluated by TBARS, 4-HNE, carbonyl, and 3-nitrotyrosine in the brain submitted to the experimental models. m-AMPH administration increased the locomotor and exploratory activities; resveratrol was not able to reverse or prevent these manic-like behaviors. Additionally, m-AMPH increased the lipid and protein oxidation and nitrosylation in the frontal cortex, hippocampus, and striatum of rats. However, resveratrol prevented and reversed the oxidative and nitrosative damage to proteins and lipids in all cerebral areas assessed. Since oxidative stress plays an important role in BD pathophysiology, supplementation of resveratrol in BD patients could be regarded as a possible adjunctive treatment with mood stabilizers.

Ahmed T, Javed S, Javed S, Tariq A, Šamec D, Tejada S, Nabavi SF, Braidy N, Nabavi SM (2017) Resveratrol and Alzheimer's disease: mechanistic insights. Mol Neurobiol 54(4):2622–2635CrossRefPubMed

Andreazza AC, Kauer-Sant'Anna M, Frey BN, Stertz L, Zanotto C, Ribeiro L, Giasson K, Valvassori SS, Réus GZ, Salvador M, Quevedo J, Gonçalves CA, Kapczinski F (2008) Effects of mood stabilizers on DNA damage in an animal model of mania. J Psychiatry Neurosci 33(6):516–524PubMedPubMedCentral

Andreazza AC, Shao L, Wang JF, Young LT (2010) Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 67(4):360–368CrossRefPubMed

Andreazza AC, Wang JF, Salmasi F, Shao L, Young LT (2013) Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. J Neurochem 127(4):552–561CrossRefPubMed

Bastin J, Djouadi F (2016) Resveratrol and myopathy. Nutrients. 8(5):E254

Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Burrows KB, Gudelsky G, Yamamoto BK (2000) Rapid and transient inhibition of mitochondrial function following methamphetamine or 3, 4-methylenedioxymethamphetamine administration. Eur J Pharmacol 398:11–18CrossRef

Berk M, Dodd S, Kauer-Sant'anna M, Malhi GS, Bourin M, Kapczinski F, Norman T (2007) Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Supplementum(434):41–49CrossRef

Broadhurst PL (1960) Experiments in psychogenetics: application of biometrical genetics to the inheritance of behavior. In: Eisenk HJ (ed) Experiments in personality: psychogenetics and psychopharmacology. Routledge & Kegan Paul, London, pp 31–71

Carrizzo A, Forte M, Damato A, Trimarco V, Salzano F, Bartolo M, Maciag A, Puca AA, Vecchione C (2013) Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem Toxicol 61:215–226CrossRefPubMed

Cobb CA, Cole MP (2015) Oxidative and nitrative stress in neurodegen eration. Neurobiol Dis 84:4–21CrossRefPubMedPubMedCentral

da-Rosa DD, Valvassori SS, Steckert AV, Ornell F, Ferreira CL, Lopes-Borges J, Varela RB, Dal-Pizzol F, Andersen ML, Quevedo J (2012a) Effects of lithium and valproate on oxidative stress and behavioral changes induced by administration of m-AMPH. Psychiatry Res 198(3):521–526CrossRefPubMed

da-Rosa DD, Valvassori SS, Steckert AV, Arent CO, Ferreira CL, Borges JL, Varela RB, Mariot E, Dal-Pizzol F, Andersen ML, Quevedo J (2012b) Differences between dextroamphetamine and methamphetamine: behavioral changes and oxidative damage in brain of Wistar rats. J Neural Transm 119:31–38CrossRefPubMed

Dawson VL, Dawson TM (1996) Nitric oxide neurotoxicity. J Chem Neuroanat 10:179–190CrossRefPubMed

de Sousa RT, Zarate CA Jr, Zanetti MV, Costa AC, Talib LL, Gattaz WF, Machado-Vieira R (2014) Oxidative stress in early stage bipolar disorder and the association with response to lithium. J Psychiatr Res 50:36–41CrossRefPubMed

Ellenbroek BA, Cools AR (1990) Animal models with construct validity for schizophrenia. Behav Pharmacol 1(6):469–490

Feier G, Valvassori SS, Lopes-Borges J, Varela RB, Bavaresco DV, Scaini G, Morais MO, Andersen ML, Streck EL, Quevedo J (2012) Behavioral changes and brain energy metabolism dysfunction in rats treated with methamphetamine or dextroamphetamine. Neurosci Lett 530:75–79CrossRefPubMed

Feier G, Valvassori SS, Varela RB, Resende WR, Bavaresco DV, Morais MO, Scaini G, Andersen ML, Streck EL, Quevedo J (2013) Lithium and valproate modulate energy metabolism in an animal model of mania induced by methamphetamine. Pharmacol Biochem Behav 103:89–96CrossRef

Floyd RA, Carney JM (1992) Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. Ann Neurol 32:22–27CrossRef

Gaballah HH, Zakaria SS, Elbatsh MM, Tahoon NM (2016) Modulatory effects of resveratrol on endoplasmic reticulum stress-associated apoptosis and oxido-inflammatory markers in a rat model of rotenone-induced Parkinson's disease. Chem Biol Interact 251:10–16CrossRefPubMed

Garthwaite J (1991) Glutamate, nitric oxide and cell–cell signaling in the nervous system. Trends Neurosci 14:60–67CrossRefPubMed

Girbovan C, Morin L, Plamondon H (2012) Repeated resveratrol administration confers lasting protection against neuronal damage but induces dose-related alterations of behavioral impairments after global ischemia. Behav Pharmacol 23:1–13CrossRefPubMed

Halliwell B (2001) Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18:685–716CrossRefPubMed

Innamorato NG, Rojo AI, García-Yague AJ, Yamamoto M, de Ceballos ML, Cuadrado A (2008) Transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 181(1):680–690

Jabben N, Arts B, van Os J, Krabbendam L (2010) Neurocognitive functioning as intermediary phenotype and predictor of psychosocial functioning across the psychosis continuum: studies in schizophrenia and bipolar disorder. J Clin Psychiatry 71(6):764–774

Kim HK, Andreazza AC, Yeung PY, Isaacs-Trepanier C, Young LT (2014) Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia. J Psychiatry Neurosci 39(4):276–285CrossRefPubMedPubMedCentral

Kumar A, Naidu PS, Seghal N, Padi SS (2007) Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. Pharmacology. 79(1):17–26CrossRefPubMed

Kunz M, Gama CS, Andreazza AC, Salvador M, Ceresér KM, Gomes FA, Belmonte-de-Abreu PS, Berk M, Kapczinski F (2008) Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 32(7):1677–1681CrossRef

Lappano R, Rosano C, Madeo A, Albanito L, Plastina P, Gabriele B, Forti L, Stivala LA, Iacopetta D, Dolce V, Andò S, Pezzi V, Maggiolini M (2009) Structure-activity relationships of resveratrol and derivatives in breast cancer cells. Mol Nutr Food Res 53(7):845–858CrossRefPubMed

Lee JM, Shih AY, Murphy TH, Johnson JA (2003) NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 278(39):37948–37956CrossRefPubMed

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–267PubMed

Magalhães PVS, Costa MH, Pinheiro RT (2016) Epidemiologia do transtorno bipolar. In: Kapczinski, F; Quevedo, J. editores. Transtorno Bipolar. Teoria e clínica. 2a ed. Porto Alegre: Artmed; pp. 17–27

Miller DK, Oelrichs CE, Sabio AS, Sun GY, Simonyi A (2013) Repeated resveratrol treatment attenuates methamphetamine-induced hyperactivity and [3H] dopamine overflow in rodents. Neurosci Lett 554:53–58CrossRefPubMed

Moi P, Chan K, Asunis I, Cao A, Kan YW (1994) Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A 91(21):9926–9930CrossRefPubMedPubMedCentral

Mokni M, Elkahoui S, Limam F, Amri M, Aouani E (2007) Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochem Res 32(6):981–987CrossRefPubMed

Morris-Blanco KC, Cohan CH, Neumann JT, Sick TJ, Perez-Pinzon MA (2014) Protein kinase C epsilon regulates mitochondrial pools of Nampt and NAD following resveratrol and ischemic preconditioning in the rat cortex. J Cereb Blood Flow Metab 34(6):1024–1032CrossRefPubMedPubMedCentral

Mur M, Portella MJ, Martinez-Aran A, Pifarre J, Vieta E (2009) Influence of clinical and neuropsychological variables on the psychosocial and occupational outcome of remitted bipolar patients. Psychopathology. 42(3):148–156CrossRefPubMed

Mustak MS, Hegde ML, Dinesh A, Britton GB, Berrocal R, Subba Rao K, Shamasundar NM, Rao KS, Sathyanarayana Rao TS (2010) Evidence of altered DNA integrity in the brain regions of suicidal victims of bipolar depression. Indian J Psychiatry 52(3):220–228CrossRefPubMedPubMedCentral

Poon HF, Calabrese V, Scapagnini G, Butterfield DA (2004) Free radicals and brain aging. Clin Geriatr Med 20(2):329–359CrossRefPubMed

Rege SD, Kumar S, Wilson DN, Tamura L, Geetha T, Mathews ST, Huggins KW, Broderick TL, Babu JR (2013) Resveratrol protects the brain of obese mice from oxidative damage. Oxidative Med Cell Longev 2013(419092):1–7CrossRef

Robb EL, Stuart JA (2011) Resveratrol interacts with estrogen receptor-β to inhibit cell replicative growth and enhance stress resistance by upregulating mitochondrial superoxide dismutase. Free Radic Biol Med 50(7):821–831CrossRefPubMed

Sawda C, Moussa C, Turner RS (2017) Resveratrol for Alzheimer's disease. Ann N Y Acad Sci 1403(1):142–149CrossRefPubMedPubMedCentral

Shah ZA, Li RC, Thimmulappa RK, Kensler TW, Yamamoto M, Biswal S, Doré S (2007) Role of reactive oxygen species in the modulation of Nrf2 after ischemic reperfusion injury. Neuroscience. 147:53–59CrossRefPubMed

Shang YJ, Qian YP, Liu XD, Dai F, Shang XL, Jia WQ, Liu Q, Fang JG, Zhou B (2009) Radical-scavenging activity and mechanism of resveratrol-oriented analogues: influence of the solvent, radical, and substitution. J Org Chem 74(14):5025–5031CrossRefPubMed

Siemann E, Creasy L (1992) Concentration of the phytoalexin resveratrol in wine am. Am J Enol Vitic 43(1):49–52

Sigitova E, Fišar Z, Hroudová J, Cikánková T, Raboch J (2017) Biological hypotheses and biomarkers of bipolar disorder. Psychiatry Clin Neurosci 71(2):77–103CrossRefPubMed

Singh KC, Kumar A, LaVoie AL, Di Pipette DJ, Singh US (2013) Diabetic complications in pregnancy: is resveratrol a solution? Exp Biol Med 238:482–490CrossRef

Siwek M, Sowa-Kucma M, Styczen K, Misztak P, Szewczyk B, Topor-Madry R, Nowak G, Dudek D, Rybakowski JK (2016) Thiobarbituric acid-reactive substances: markers of an acute episode and a late stage of bipolar disorder. Neuropsychobiology. 73(2):116–122CrossRefPubMed

Stringer D, Marshall D, Pester B, Baker A, Langenecker SA, Angers K, Frazier N, Archer C, Kamali M, McInnis M, Ryan KA (2014) Openness predicts cognitive functioning in bipolar disorder. J Affect Disord 168:51–57CrossRefPubMed

Sun D, Yue Q, Guo W, Li T, Zhang J, Li G, Liu Z, Sun J (2015) Neuroprotection of resveratrol against neurotoxicity induced by methamphetamine in mouse mesencephalic dopaminergic neurons. Biofactors. 41(4):252–260CrossRefPubMed

Tadolini B, Juliano C, Piu L, Franconi F, Cabrini L (2000) Resveratrol inhibition of lipid peroxidation. Free Radic Res 33(1):105–114CrossRefPubMed

Tata DA, Yamamoto BK (2007) Interactions between methamphetamine and environmental stress: role of oxidative stress, glutamate and mitochondrial dysfunction. Addiction. 1:49–60CrossRef

Teixeira AL, Salem H, Frey BN, Barbosa IG, Machado-Vieira R (2016) Update on bipolar disorder biomarker candidates. Expert Rev Mol Diagn 16(11):1209–1220CrossRefPubMed

Tellone E, Galtieri A, Russo A, Giardina B, Ficarra S (2015) Resveratrol: a focus on several neurodegenerative diseases. Oxidative Med Cell Longev 2015:392169CrossRef

Tsai MC, Huang TL (2015) Thiobarbituric acid reactive substances (TBARS) is a state biomarker of oxidative stress in bipolar patients in a manic phase. J Affect Disord 173:22–26CrossRefPubMed

Valvassori SS, Elias G, de Souza B, Petronilho F, Dal-Pizzol F, Kapczinski F, Trzesniak C, Tumas V, Dursun S, Chagas MH, Hallak JE, Zuardi AW, Quevedo J, Crippa JA (2011) Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychopharmacol 25(2):274–280CrossRefPubMed

Vargas MR, Johnson JA (2009) The Nrf2-ARE cytoprotective pathway in astrocytes. Expert Rev Mol Med 11:e17CrossRefPubMedPubMedCentral

Wang JF, Shao L, Sun X, Young LT (2009) Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 11(5):523–529CrossRefPubMed

Whitlock NC, Baek SJ (2012) The anticancer effects of resveratrol: modulation of transcription factors. Nutr Cancer 64(4):493–502CrossRefPubMedPubMedCentral

Xie W, Ge X, Li L, Yao A, Wang X, Li M, Gong X, Chu Z, Lu Z, Huang X, Jiao Y, Wang Y, Xiao M, Chen H, Xiang W, Yao P (2018) Resveratrol ameliorates prenatal progestin exposure-induced autism-like behavior through ERβ activation. Mol Autism 9:43CrossRefPubMedPubMedCentral

Yui K, Kawasaki Y, Yamada H, Ogawa S (2016) Oxidative stress and nitric oxide in autism spectrum disorder and other neuropsychiatric disorders. CNS Neurol Disord Drug Targets 15(5):587–596CrossRefPubMed

Title: Resveratrol protects the brain against oxidative damage in a dopaminergic animal model of mania
Authors: Samira Menegas
Camila L. Ferreira
José Henrique Cararo
Fernanda F. Gava
Gustavo C. Dal-Pont
Maria L. Gomes
Jotele F. Agostini
Patrícia Fernanda Schuck
Giselli Scaini
Monica L. Andersen
João Quevedo
Samira S. Valvassori
Publication date: 01-06-2019
Publisher: Springer US
Published in: Metabolic Brain Disease / Issue 3/2019
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-019-00408-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Resveratrol protects the brain against oxidative damage in a dopaminergic animal model of mania

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Fluoro-Jade B histofluorescence staining detects dentate granule cell death after repeated five-minute transient global cerebral ischemia

Immune-inflammatory, oxidative stress and biochemical biomarkers predict short-term acute ischemic stroke death

Neuroprotective effect of grape seed extract on brain ischemia: a proteomic approach

Safflower yellow attenuates learning and memory deficits in amyloid β-induced Alzheimer’s disease rats by inhibiting neuroglia cell activation and inflammatory signaling pathways

GRM7 polymorphisms and risk of schizophrenia in Iranian population

Association of PTTG1 polymorphism rs1895320, rs2910200 and rs6882742 with non-functioning pituitary adenomas in Chinese Han population: a case-control study